CymaBay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

CymaBay Therapeutics

10/08/2023 22:02

* CymaBay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted
loss of 1 cent​​ per share for the quarter ended in June. The
mean expectation of eleven analysts for the quarter was for a
loss of 20 cents per share.
    * Revenue was $31.02 million​; analysts expected $9.90
million. 
    * CymaBay Therapeutics Inc's reported EPS for the quarter
was a
loss of 1 cent​.
    * The mean earnings estimate of analysts had risen by
about 27% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * CymaBay Therapeutics Inc shares had risen by 15.3% this
quarter and gained 101.4% so far this year.
    * The company reported a quarterly loss of $808 thousand.
    * Wall Street's median 12-month price target for CymaBay
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.20          -0.01          Beat
 Mar. 31 2023      -0.09          -0.29          Missed
 Dec. 31 2022      -0.30          -0.30          Met
 Sep. 30 2022      -0.30          -0.28          Beat